Figure 5: FGFRL1 is a downstream target of miR-187-3p in prostate cancer. (a) Volcano plot of differentially expressed mRNAs in prostate cancer in The Cancer Genome Atlas (TCGA) database, in which red dots and green dots indicate upregulated and downregulated mRNAs in prostate cancer, respectively. (b) Venn diagram of the intersection of mRNAs sharing the binding site with miR-187-3p in starBase and mirDIP databases and DEmiRNAs in prostate cancer in TCGA database. (c) Heat plot about the correlation analysis on expressions of miR-187-3p and 7 mRNAs (HOXC9, GATA4, ERG, GBX2, CAMK2N2, LRFN1, and FGFRL1) in TCGA database. (d) FGFRL1 level in prostate cancer tissues (red) and normal tissues (green) in TCGA database. (e) Gene expression of FGFRL1 in RWPE-1, VCaP, PC-3, and DU-145 cells was assessed through quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). *P < 0.05 relative to RWPE-1 group, n = 3. (f) Western blot was done to test the protein level of FGFRL1 in cells. (g) Binding site of miR-187-3p and FGFRL1-WT in starBase database. (h) Binding relationship of miR-187-3p and FGFRL1 was identified through conducting a dual-luciferase assay. *P < 0.05 relative to FGFRL1-Wt + NC-mimic group, n = 3. (i) The effects of overexpression or inhibition of miR-187-3p on the expression of VPS9D1-AS1 and FGFRL1 in PC-3 cells were tested by qRT-PCR assay. *P < 0.05 relative to NC-mimic group, n = 3. (j) The effect of overexpression or inhibition of miR-187-3p on FGFRL1 protein level in PC-3 cells was evaluated by Western blot.